



# SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2025-26/BSE/25

Dated:06.02.2026

To,

Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting held on 06<sup>TH</sup> February 2026 with Scrip Code 524703.

Ref: Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations.  
2015

A Meeting of the Board of Directors of the Company duly convened on Friday, 06<sup>th</sup> February 2026 at 04:00 p.m. and concluded at 05:30 p.m. discussed the following business: -

1. The Unaudited Standalone Financial Results of the Company for the quarter and Period ended 31<sup>st</sup> December 2025 and the Limited Review Report issued by M/s. Dileep & Prithvi, Chartered Accountants, Mumbai, [Firm Registration. No. 122290W], Statutory Auditors of the Company pursuant to Regulation 33 of Chapter IV of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and placed before the Board of Directors of the Company in their meeting held today. The same are approved and taken on record by the Board.

The Unaudited Standalone Financial Results for the quarter and period ended 31<sup>st</sup> December 2025 and the Limited Review Report will also be made available at the website of the company at [www.sandu.in](http://www.sandu.in) and are enclosed herewith for your kind perusal.

FOR SANDU PHARMACEUTICALS LTD.

Pratika Mhambray  
Company Secretary & Compliance Officer  
ACS :36512



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





# SANDU PHARMACEUTICALS LIMITED

CIN: L24233GA10B5PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

## SANDU PHARMACEUTICALS LIMITED

### STANDLONE STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 31st Dec 2025

(Rs in Lakhs)

Particulars	Quarter Ended			Nine Months ended		Previous Year Ended 31st March 2025 (Audited)
	31-12-2025 (Un audited)	30-09-2025 (Un audited)	31-12-2024 (Un audited)	31-12-2025 (Un Audited)	31-12-2024 (Un audited)	
Revenue From Operations	1876.09	1762.11	1837.29	5308.10	5312.32	6719.24
Other Income	1.37	4.79	2.45	7.93	9.81	16.75
<b>Total Income (I+II)</b>	<b>1877.46</b>	<b>1766.91</b>	<b>1839.74</b>	<b>5316.04</b>	<b>5322.13</b>	<b>6735.99</b>
<b>EXPENSES</b>						
Cost of materials consumed	281.31	244.85	239.21	717.24	710.48	1011.98
Purchases of Stock-in-Trade	349.94	587.84	654.78	1296.54	1589.52	2318.45
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	157.47	.02	-7.74	490.96	332.33	-120.24
Employee benefits expense	264.65	263.79	315.71	794.80	809.29	1092.03
Finance costs	3.35	2.66	2.74	8.64	7.70	10.33
Depreciation and amortization expense	16.58	16.87	18.96	51.21	52.24	67.06
Other expenses	718.66	579.42	536.23	1765.82	1639.24	2140.80
<b>Total expenses (IV)</b>	<b>1791.96</b>	<b>1695.46</b>	<b>1759.89</b>	<b>5125.21</b>	<b>5140.80</b>	<b>6520.41</b>
Profit/(loss) before exceptional items and tax (I- IV)	85.50	71.45	79.85	190.83	181.33	215.58
Exceptional Items						
Profit/(loss) before tax (V-VI)	85.50	71.45	79.85	190.83	181.33	215.58
Tax expense:						
(1) Current tax	-4.89	19.71	22.92	24.51	51.45	58.86
(2) Deferred tax	-7.12	.54	1.38	-5.95	7.65	1.83
Short / ( Excess ) Tax Provision	.00	-1.22	.00	.00	.00	.00
Profit (Loss) for the period from continuing operations (VII-VIII)	97.51	52.43	55.55	172.27	122.25	154.89
Profit/(loss) for the period (IX+XII)	97.51	52.43	55.55	172.27	122.25	154.89
Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss						
a. Remeasurement gains/(losses) on post employment defined benefit plans						-12.66
b. Fair value changes of investments	19.70	16.13	20.54	55.45	61.60	82.95
(ii) Income tax relating to items that will not be reclassified to profit or loss	-2.74	-2.24	-2.29	-14.29	-6.86	-5.71
B (i) Items that will be reclassified to profit or loss						
(ii) Income tax relating to items that will be reclassified to profit or loss						
Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit(Loss) and Other Comprehensive Income for the period)	114.47	66.31	73.80	213.43	176.99	219.47
Paid Up Equity Capital ( Face Value of Rs. 10/- Per share )	966.10	966.10	966.10	966.10	966.10	966.10
Earnings per equity share (for continuing operation):						
(1) Basic	1.01	0.54	0.57	1.78	1.27	1.60
(2) Diluted	1.01	0.54	0.57	1.78	1.27	1.60

For Sandu Pharmaceuticals Ltd

Umesh Sandu  
Managing Director  
DIN :- 01132141

Place :- Mumbai  
Date :- 06/02/2026

AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.  
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





# SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 06/02/2026.
4. The Figures for the quarter ended 31 st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.

For Sandu Pharmaceuticals Ltd

Date: - 06/02/2026

Umesh Sandu  
Managing Director  
DIN no: - 01132141



ISO 9001:2015 CERTIFIED ORGANISATION

AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in




**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE  
FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31<sup>st</sup> DECEMBER,  
2025**

To,  
**The Board of Directors,**  
**Sandu Pharmaceuticals Limited,**  
Plot No. 25, 26, 29 & 30,  
Pilerne Industrial Estate, Marra,  
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and nine months ended on 31<sup>st</sup> December, 2025, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Dileep & Prithvi**  
Chartered Accountants  
Firm Registration Number: 122290W



**Himmat Mali**  
(Partner)  
Membership Number: 183378  
UDIN- 26183378DWHJKM9406



Place: Mumbai  
Date: 6<sup>th</sup> February, 2026